Leveraging AlphaFold2 Structural Space Exploration for Generating Drug Target Structures in Structure-Based Virtual Screening

In early drug discovery, computational virtual screening (VS) is vital for selecting candidate compounds and reducing costs. However, the lack of experimentally determined 3D structures has limited the application of structure-based VS. Advances in protein structure prediction, notably AlphaFold2, have begun to address this gap. Yet, studies indicate that direct use of AlphaFold2-predicted structures often leads to suboptimal VS performance—likely because these structures fail to capture ligand-induced conformational changes (apo-to-holo transitions). To overcome this, we propose an approach that explores and modifies the structural space of AlphaFold2 predictions to generate conformations more amenable to VS. Our method deliberately alters the multiple sequence alignment (MSA) by introducing alanine mutations at key residues in the ligand-binding site, thereby inducing significant conformational shifts. The exploration process is guided by iterative ligand docking simulations, with mutation strategies optimized either by a genetic algorithm or via random search. Our evaluation shows that when sufficient active compounds are available, the genetic algorithm significantly enhances VS accuracy. In contrast, with limited active compound data, a random search strategy proves more effective. Moreover, our approach is particularly promising for targets that yield poor screening results when using experimentally determined structures from the PDB. Overall, these findings underscore the practical utility of modified AlphaFold2-derived structures in VS and expand the potential of computationally predicted protein models in drug discovery.